piwik-script

Intern
    Onkologische Forschung

    Michael Hudecek: CAR T-cell Engineering

    Summary

    Our group is working in the field of tumor immunology and our efforts are directed at the development and clinical translation of adoptive immunotherapy of cancer with tumor-specific T cells. A recent focus in the lab is the engineering of T cells that have been modified by gene transfer to express tumor-targeting chimeric antigen receptors (CARs). CARs are synthetic receptors with an extracellular antigen-binding domain derived from the variable heavy and light chains of a monoclonal antibody and an intracellular signaling module that mediates T-cell activation after antigen-binding. We are working on defining target molecules that are expressed on malignant cells but not on vital normal tissues and can be targeted by CAR T cells, and deriving insights into how to best design these receptors in order to confer optimum tumor recognition and T-cell activation. 

    Recent Publications

    Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia. Prommersberger S, Jetani H, Danhof S, Monjezi R, Nerreter T, Beckmann J, Einsele H, Hudecek M. Curr Res Transl Med. 2018 Apr 11.[Epub ahead of print]

    CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, Hudecek M. Leukemia. 2018 Feb 5. [Epub ahead of print]

    Current developments in immunotherapy in the treatment of multiple myeloma. Köhler M, Greil C, Hudecek M, Lonial S, Raje N, Wäsch R, Engelhardt M. - Cancer. 2018 Feb 6. [Epub ahead of print] Review.

    Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance. Danhof S, Schreder M, Knop S, Rasche L, Strifler S, Löffler C, Gogishvili T, Einsele H, Hudecek M. Haematologica. 2018 Mar;103(3):e126-e129.

    SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, Einsele H, Hudecek M. Blood. 2017 Dec 28;130(26):2838-2847.

    Kontakt

    Comprehensive Cancer Center Mainfranken
    Haus C16
    Josef-Schneider Str. 6
    97080 Würzburg

    Tel.: +49 931 201-35350
    Fax: +49 931 201-35359
    E-Mail

    Suche Ansprechpartner

    Campus Medizin
    Campus Medizin